Compare Johnson & Johnson (JNJ) vs Paychex, Inc. (PAYX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Paychex, Inc. — how do they compare? Johnson & Johnson trades at $260.68 (market cap $626.09B), while Paychex, Inc. trades at $119.41 (market cap $43.14B). The key difference: Johnson & Johnson is far larger — about 14.5× Paychex, Inc.'s market cap, and Paychex, Inc. pays the higher dividend (3.92%). Which is the better fit depends on your goals.
| JNJ | PAYX | |
|---|---|---|
Market Cap | $626.09B | $43.14B |
Volume | 6,156,228 | — |
Sector | Health | Industrials |
52-Week High | $267.24 | $140.81 |
52-Week Low | $172.78 | $85.57 |
Enterprise Value | $654.37B | $46.63B |
Dividend Yield | 2.06% | 3.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.
Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.
Paychex (PAYX) trades at $119.93, down 1.03% today, with a bullish technical outlook and strong profitability. Recent quarters show consistent earnings beats, with Q2 2026 EPS expected at $1.33. The company maintains robust margins, including a 27.03% net income margin, and pays a steady dividend of $1.19 quarterly. Cash flow trends indicate operational strength, though 2025 saw significant investing outflows.
The stock presents a mixed outlook: solid fundamentals and dividend appeal are offset by a consensus 'Hold' rating and a price target below the current level. Risks include high valuation multiples and potential economic sensitivity for small business clients. Upside depends on sustained earnings growth and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Paychex, Inc.
Paychex is a leading provider of payroll, human capital management, and insurance solutions servicing small and midsize clients primarily in the United States. The company, established in 1979, services over 730,000 clients and pays over 1 in 12 U.S. private-sector workers. Alongside its traditional payroll services, Paychex offers HCM solutions such as benefits administration and time and attendance software, as well as human resources outsourcing and insurance agency services.
Read more on PAYX →
